Short Interest in Prenetics Global Limited (NASDAQ:PRE) Decreases By 24.7%

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 32,600 shares, a decline of 24.7% from the January 15th total of 43,300 shares. Based on an average daily volume of 14,000 shares, the days-to-cover ratio is presently 2.3 days. Currently, 0.4% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $9.00 price objective on shares of Prenetics Global in a research note on Thursday, January 16th.

Prenetics Global Stock Down 1.2 %

Prenetics Global stock traded down $0.07 during trading hours on Friday, hitting $5.44. The stock had a trading volume of 1,295 shares, compared to its average volume of 20,145. Prenetics Global has a 1-year low of $2.85 and a 1-year high of $7.84. The stock’s fifty day moving average is $5.57 and its two-hundred day moving average is $5.03.

Prenetics Global (NASDAQ:PRE) last posted its earnings results on Wednesday, November 27th. The company reported ($0.84) earnings per share for the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. Analysts predict that Prenetics Global will post -3.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new stake in shares of Prenetics Global Limited (NASDAQ:PRE) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global as of its most recent SEC filing. Institutional investors own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.